



Adherium to present at Respiratory Drug Delivery Europe 2017

Melbourne, Australia, 11 April 2017, Adherium Limited (ASX: ADR, 'Adherium'), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, will be presenting at the Respiratory Drug Delivery Europe conference 2017 (RDD Europe), being held at the Palais des Congres d'Antibes in Nice, France, from 25-28 April 2017.

Adherium's Group CEO, Garth Sutherland, will present 'Track and Remind: Can Connected Devices Improve Patient Medication Adherence?' in Session Three "Can Connected Devices Improve Respiratory Outcomes?" at 9:30am on Thursday 27 April 2017.

The presentation will focus on the recognized problem of adherence to preventative medication and how Adherium's Smartinhaler™ platform has demonstrated its ability to improve patient engagement and treatment effectiveness. The presentation will coincide with the publication of Adherium's article of the same name in RDD's peer reviewed journal *Respiratory Drug Delivery Europe 2017*.

Garth Sutherland, Group CEO of Adherium said: "Adherium has created the largest, most robust and comprehensive body of peer-reviewed evidence in the world supporting the benefit of electronic respiratory drug delivery technology for patients, their caregivers, and their healthcare professionals. I am looking forward to disseminating this information to Adherium's industry partners and colleagues at this most prestigious event."

ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium operates globally from bases in the USA, Europe and Australasia.

Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company's proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

Enquiries:

At Adherium:	Media enquiries:
<p>Investor Relations at Adherium: Julia Chambers Head of Corporate Development M: +64 27 807 8153 E: investors@adherium.com</p>	
<p>Rest of World Erin Wansbrough Vice President Business Development Rest of World M: +64 21 766 083 E: erinw@adherium.com</p>	<p>Australia and New Zealand Rudi Michelson Monsoon Communications D: +61 3 9620 3333 E: rudim@monsoon.com.au</p>
<p>North America James Hattersley Senior Vice President Business Development North America M: +1 610 955 5886 E: jamesh@adherium.com</p>	<p>North America Erich Sandoval Lazar Partners D: +1 213-908-6226 E: esandoval@lazarpartners.com</p>
<p>Europe Scott Fleming Senior Vice President Business Development Europe M: +31 646 876 989 E: scottf@adherium.com</p>	<p>Europe Sue Charles/Tim Watson Instinctif Partners D: +44 20 7457 2020 E: adherium@instinctif.com</p>